| 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. | |
| | |
MedLine Citation:
|
PMID: 21251625 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The purpose of this study was to evaluate the long-term outcomes of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. BACKGROUND: In primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction (STEMI), the use of drug-eluting stents (DES) is still controversial. Several randomized controlled trials of DES, compared with bare-metal stents (BMS), with short-term follow-up showed a reduction in target lesion revascularization (TLR), but no differences in rates of cardiac death or recurrent myocardial infarction. Moreover, the occurrence of (very) late stent thrombosis (ST) continues to be of major concern, and, therefore, long-term follow-up results are needed. METHODS: We randomly assigned 619 patients presenting with STEMI to a paclitaxel-eluting stent (PES) or the similar BMS. The primary end point was the composite of cardiac death, recurrent myocardial infarction, or TLR. We performed clinical follow-up at 5 years. RESULTS: At 5 years, the occurrence of the composite of cardiac death, recurrent myocardial infarction, or TLR was comparable at 18.6% versus 21.8% in PES and BMS, respectively (hazard ratio [HR]: 0.82, 95% confidence interval [CI]: 0.58 to 1.18, p = 0.28). The incidence of definite or probable ST was 12 (4.2%) in the PES group and 10 (3.4%) in the BMS group (HR: 1.19, 95% CI: 0.51 to 276, p = 0.68). CONCLUSIONS: In the present analysis of PES compared with BMS in primary percutaneous coronary intervention for STEMI, no significant difference in major adverse cardiac events was observed. In addition, no difference in the incidence of definite or probable ST was seen, although very late ST was almost exclusively seen after the use of PES. (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation [PASSION]; ISRCTN65027270). |
| | |
Authors:
|
Maarten A Vink; Maurits T Dirksen; Maarten J Suttorp; Jan G P Tijssen; Jeroen van Etten; Mark S Patterson; Ton Slagboom; Ferdinand Kiemeneij; Gerrit J Laarman |
Related Documents
:
|
21697605 - Additive effects of β-blockers on renin-angiotensin system inhibitors for patients aft... 21971845 - Myocardial area at risk after st-elevation myocardial infarction measured with the late... 22286325 - Percutaneous occlusion of left atrial appendage with the amplatzer cardiac plugtm in at... 2572255 - Long-term studies with xamoterol in heart failure. 7798505 - Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: eff... 11078265 - Quality of life after coronary revascularization in the united states and canada. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JACC. Cardiovascular interventions Volume: 4 ISSN: 1876-7605 ISO Abbreviation: JACC Cardiovasc Interv Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-21 Completed Date: 2011-05-03 Revised Date: 2012-08-29 |
Medline Journal Info:
|
Nlm Unique ID: 101467004 Medline TA: JACC Cardiovasc Interv Country: United States |
Other Details:
|
Languages: eng Pagination: 24-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. m.a.vink@olvg.nl |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ISRCTN/ISRCTN65027270 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Balloon, Coronary
/
adverse effects,
instrumentation*,
mortality Cardiovascular Agents / administration & dosage* Drug-Eluting Stents* Follow-Up Studies Humans Kaplan-Meier Estimate Metals* Myocardial Infarction / mortality, therapy* Netherlands Paclitaxel / administration & dosage* Proportional Hazards Models Prospective Studies Recurrence Risk Assessment Risk Factors Single-Blind Method Stents* Thrombosis / etiology Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents; 0/Metals; 33069-62-4/Paclitaxel |
| Comments/Corrections | |
Comment In:
|
JACC Cardiovasc Interv. 2011 Jan;4(1):39-41
[PMID:
21251627
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary ste...
Next Document: Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug...